The management of struggling biotech Zymeworks has rejected a $773m takeover bid from activist investor All Blue Capital, saying the “opportunistic” offer lacks credibility and undervalues the company.
The $10.50 per share cash offer represents more than double the biotech’s current market valuation, which has plunged by nearly...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
